Yucai Wang

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics.

American journal of hematology · Apr 17, 2026

Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.

Cancer · Apr 15, 2026

Next-Generation Sequencing for Lymphoid Neoplasms: Real-World Utility from a Clinical Assay.

Human pathology · Apr 11, 2026

Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.

Blood cancer journal · Apr 8, 2026

Mitochondrial ACSS1 Links Acetate Metabolism to Pyrimidine Biosynthesis in Nutrient-Stressed B-Cell Lymphomas.

Cancer letters · Apr 7, 2026

Targeting UHRF1 induces regression of aggressive mantle cell lymphoma.

Leukemia · Mar 24, 2026

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.

Blood · Mar 19, 2026

Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.

Clinical lymphoma, myeloma & leukemia · Mar 17, 2026

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.

Blood advances · Mar 10, 2026

Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.

British journal of haematology · Mar 10, 2026

Inhibition of CDC20 suppresses the development and progression of mantle cell lymphoma through PI3K/AKT pathway.

Annals of hematology · Mar 9, 2026

Clinical characteristics and prognostic features of patients with blastoid and pleomorphic variant mantle cell lymphoma: a real-world study in China.

Annals of hematology · Mar 7, 2026

Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis.

Leukemia & lymphoma · Mar 7, 2026

Proteogenomic features define subtypes of mantle cell lymphoma.

Blood advances · Mar 5, 2026

Cell-free chromatin state tracing reveals disease origin and therapy responses.

Nature · Mar 4, 2026

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Clinical cancer research : an official journal of the American Association for Cancer Research · Mar 2, 2026

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Blood advances · Feb 24, 2026

Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.

Experimental hematology & oncology · Feb 11, 2026

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy.

Future oncology (London, England) · Feb 1, 2026

TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.

Annals of hematology · Jan 21, 2026

A novel immune model predicts the prognosis of mantle cell lymphoma.

Frontiers in medicine · Jan 1, 2026

Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside.

Research (Washington, D.C.) · Jan 1, 2026

May obesity increase the risk of lymphoma? Insights from genetic evidence.

Expert review of hematology · Jan 1, 2026

SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma.

Blood advances · Dec 23, 2025

Mantle Cell Lymphoma Presenting as a Primary Cutaneous Mass: A Case Report.

Acta dermato-venereologica · Dec 7, 2025

Suspicious Laryngeal Mass: A Case Of Recurrent Mantle Cell Lymphoma.

Ear, nose, & throat journal · Dec 1, 2025

Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study.

Annals of medicine · Dec 1, 2025

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study.

NPJ precision oncology · Nov 21, 2025

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.

Blood · Nov 20, 2025

Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.

Blood advances · Nov 11, 2025

Mantle cell lymphoma presenting primarily as cutaneous lesions: A case report.

World journal of clinical cases · Nov 6, 2025

Albumin nanocomplex of BCL-2/xL inhibitor reduced platelet toxicity and improved anticancer efficacy in myeloproliferative neoplasm and lymphoma.

Biomaterials · Nov 1, 2025

Cyclin-D1 rearrangement as a secondary event in the large cell transformation of splenic marginal zone lymphoma with a TP53 deletion.

Virchows Archiv : an international journal of pathology · Nov 1, 2025

Patient-derived organoid modeling predicts personalized drug responses in prostate-metastatic mantle cell lymphoma: a case report.

Anti-cancer drugs · Nov 1, 2025

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.

Blood advances · Oct 28, 2025

YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma.

Blood advances · Oct 14, 2025

Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma.

American journal of hematology · Oct 1, 2025

Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase.

Journal of virology · Sep 23, 2025

Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma.

Cell reports. Medicine · Sep 16, 2025

Transcriptional Analysis of Effusion-Based Lymphoma Supports a Post-Germinal Center Origin and Specific Inflammatory Signal Background.

Cancers · Sep 12, 2025

Acalabrutinib alleviates metabolic dysfunction-associated steatotic liver disease by regulating bile acid metabolism.

The international journal of biochemistry & cell biology · Aug 1, 2025

Nuclear Receptor-Binding SU(VAR)3-9, Enhancer of Zeste, Trithorax Domain Structural Domain Protein 2 Serves as a Potential Prognostic Biomarker in Mantle Cell Lymphoma.

Laboratory investigation; a journal of technical methods and pathology · Aug 1, 2025

CBX5 loss drives Pl3Kδ inhibitor resistance in mantle cell lymphoma and propolis restores sensitivity by inducing CBX5-mediated ferroptosis.

Phytomedicine : international journal of phytotherapy and phytopharmacology · Jul 25, 2025

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025

IGH/IGK gene rearrangement in the diagnosis of B-cell non-Hodgkin lymphoma: experience from three centers.

Annals of hematology · Jul 1, 2025

Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance.

Journal of advanced research · Jul 1, 2025

Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status.

Blood · Jun 19, 2025

Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy.

Clinical lymphoma, myeloma & leukemia · Jun 1, 2025

Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Clinical lymphoma, myeloma & leukemia · Jun 1, 2025

CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma.

Nature communications · May 29, 2025

Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma.

Cancer cell international · May 3, 2025

SQSTM1/p62 predicts prognosis and upregulates the transcription of CCND1 to promote proliferation in mantle cell lymphoma.

Protoplasma · May 1, 2025

A novel research model of clonal evolution in mantle cell lymphoma at the single-cell genomic level.

Genes & diseases · May 1, 2025

Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.

Leukemia & lymphoma · May 1, 2025

Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH::CCND1.

Human pathology · May 1, 2025

Mantle cell lymphoma with a prominent intrasinusoidal pattern of bone marrow involvement and circulating "prolymphocytoid" cells: an unusual pathological presentation posing diagnostic pitfalls.

Journal of hematopathology · Apr 15, 2025

[Composite diffuse large B-cell lymphoma and CD5-negative mantle cell lymphoma: report of a case].

Zhonghua bing li xue za zhi = Chinese journal of pathology · Apr 8, 2025

Small-molecule BTK inhibitors: From discovery to clinical application.

Bioorganic chemistry · Apr 1, 2025

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma.

Annals of hematology · Apr 1, 2025

Impact of splenectomy on prognosis in lymphoma with splenic involvement.

European journal of medical research · Mar 28, 2025

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.

The Journal of clinical investigation · Mar 17, 2025

POD24-Based prognostic signature enables personalized risk stratification in mantle cell lymphoma.

Scientific reports · Mar 13, 2025

Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma.

Cancer biology & medicine · Mar 12, 2025

Challenges of treating mantle cell lymphoma in older adults.

Leukemia & lymphoma · Mar 1, 2025

Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.

Haematologica · Mar 1, 2025

The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma.

Annals of hematology · Mar 1, 2025

Causal Associations of Gut Microbiota Species With Lymphoma: A Two-Sample Mendelian Randomization Study.

Hematological oncology · Mar 1, 2025

Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping.

Annals of hematology · Mar 1, 2025

[Indolent leukemic non-nodal mantle cell lymphoma with TP53 mutation misdiagnosed as chronic lymphocytic leukemia: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · Feb 14, 2025

High-risk MCL: recognition and treatment.

Blood · Feb 13, 2025

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

The Lancet. Oncology · Feb 1, 2025

Development of a novel prognostic model for mantle cell lymphoma based on quantitative detection of CD3 by quantitative dot blot.

Frontiers in oncology · Jan 1, 2025

Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis.

Frontiers in pharmacology · Jan 1, 2025

Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway.

Current molecular medicine · Jan 1, 2025

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

Haematologica · Jan 1, 2025

Novel therapeutic agents and intensive chemotherapy improve survival outcomes in patients with mantle cell lymphoma.

American journal of cancer research · Jan 1, 2025

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.

Nature reviews. Clinical oncology · Dec 1, 2024

Clinical significance of Cyclin D1 by complete quantification detection in mantle cell lymphoma: positive indicator in prognosis.

Diagnostic pathology · Nov 21, 2024

Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center.

Leukemia & lymphoma · Nov 1, 2024

Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.

Leukemia & lymphoma · Nov 1, 2024

Prognostic significance and biological implications of SM-like genes in mantle cell lymphoma.

Blood research · Oct 17, 2024

Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.

Nature communications · Oct 7, 2024

Simultaneous Determination of Ibrutinib, Dihydroxydiol Ibrutinib, and Zanubrutinib in Human Plasma by Liquid Chromatography-Mass Spectrometry/Mass Spectrometry.

Therapeutic drug monitoring · Oct 1, 2024

Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Expert review of hematology · Oct 1, 2024

Ultrasound findings of non-Hodgkin's mantle cell lymphoma in the right inguinal region.

Medical ultrasonography · Sep 16, 2024

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.

Blood advances · Sep 10, 2024

Warthin tumor concomitant with mantle cell lymphoma: a case report and review of literature.

Diagnostic pathology · Aug 24, 2024

PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma.

Cancer letters · Aug 10, 2024

Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma.

Virchows Archiv : an international journal of pathology · Aug 1, 2024

Mantle cell lymphoma characterized by numerous diffuse polypoid lesions along the entire digestive tract: A case report.

Oncology letters · Aug 1, 2024

Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition.

Journal of translational medicine · Jul 4, 2024

Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China.

Annals of hematology · Jul 1, 2024

The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.

Leukemia · Jul 1, 2024

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma.

Biomarker research · Jun 18, 2024

[Clinicopathological features and prognosis analysis of bone marrow biopsy involvement in 95 cases with mantle cell lymphoma].

Zhonghua bing li xue za zhi = Chinese journal of pathology · Jun 8, 2024

[Intestinal Mantle Cell Lymphoma Complicated With Ileocecal Intussusception in Adults:Report of One Case].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae · Jun 1, 2024

Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib.

ACG case reports journal · Jun 1, 2024

PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma.

Cancer letters · Jun 1, 2024

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.

The Journal of clinical investigation · May 15, 2024

[Progressive necrotizing xanthogranuloma in both eyes: a case report].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology · May 11, 2024

Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.

Leukemia & lymphoma · May 1, 2024

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.

Hematological oncology · May 1, 2024

Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.

Leukemia & lymphoma · May 1, 2024

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.

Blood advances · Apr 23, 2024

Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma.

Discover oncology · Apr 5, 2024

TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.

Human pathology · Apr 1, 2024

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Apr 1, 2024

Clinical Warburg Effect in a Patient With Mantle Cell Lymphoma: A Case Report.

Cureus · Apr 1, 2024

The influence of marital status at diagnosis on survival of adult patients with mantle cell lymphoma.

Journal of cancer research and clinical oncology · Mar 11, 2024

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Blood advances · Feb 27, 2024

Genetically predicted telomere length and the risk of 11 hematological diseases: a Mendelian randomization study.

Aging · Feb 22, 2024

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.

Experimental hematology & oncology · Feb 7, 2024

[Effect of Chlorambucil Combined with Ibrutinib on Mantle Cell Lymphoma Cell Line Jeko-1 and Its Related Mechanism].

Zhongguo shi yan xue ye xue za zhi · Feb 1, 2024

Mantle Cell Lymphoma Presenting as Erosive Duodenitis.

The American journal of gastroenterology · Feb 1, 2024

Novel BRAF N581S mutation in mantle cell lymphoma.

EJHaem · Feb 1, 2024

SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Feb 1, 2024

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research · Jan 5, 2024

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.

Frontiers in immunology · Jan 1, 2024

Socioeconomic status, individual behaviors and risk for Lymphomas: a Mendelian randomization study.

Journal of Cancer · Jan 1, 2024

Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.

PloS one · Jan 1, 2024

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.

Haematologica · Jan 1, 2024

Ferroptosis-related prognostic model of mantle cell lymphoma.

Open medicine (Warsaw, Poland) · Jan 1, 2024

Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma.

Journal of medical economics · Jan 1, 2024

LINK-A: unveiling its functional role and clinical significance in human tumors.

Frontiers in cell and developmental biology · Jan 1, 2024

STAT5B Suppresses Ferroptosis by Promoting DCAF13 Transcription to Regulate p53/xCT Pathway to Promote Mantle Cell Lymphoma Progression.

Biologics : targets & therapy · Jan 1, 2024